BioNTech: Vaccine Decline Meets Promising Lung Cancer Approach
Reading Time: 2 minutes
BioNTech is forcing the transition from a vaccine manufacturer to a diversified oncology company. Data from September 14, 2026, demonstrate a significantly extended survival time in lung cancer patients. Declining Covid-19 revenues necessitate a consistent realignment under new leadership. From Pandemic Beneficiary to Cancer Specialist BioNTech (BNTX) is currently undergoing a profound transformation. The business model reliant on Covid-19 vaccines is being systematically reoriented. In August 2026, the company lowered its annual forecast...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
